PPT-THERAPY Trial

ESO Conference Glasgow Scotland April 17 2015 J Mocco 1 Osama Zaidat 2 Rüdiger von Kummer 3 Albert Yoo 4 Rishi Gupta 5 Demetrius Lopes 6 Don Frei 7 Pooja Khatri. cell based therapies in the UK. . Natalie Mount PhD. Chief Clinical Officer. Cell Therapy Catapult. Nov 2013. natalie.mount@ct.catapult.org.uk. UK Catapults. 2. Catapults . are core funded by the Technology Strategy Board as ‘not for profit’ companies to . Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. in non-Her2 breast cancer. . 10/4/16. Objectives. Rationale for neoadjuvant chemo. Patient selection. Chemo regimens. Surgical considerations- breast and axilla. Special populations- triple . Triple Negative Breast Cancer. Steven J. Isakoff, MD, PhD. Dana-Farber . Harvard Cancer . Center/ Massachusetts General Hospital Cancer . Center. August 19, 2017. sisakoff@partners.org. 46 year-old premenopausal woman . Dr Howard L. McLeod. Medical Director, DeBartolo Family. Personalized Medicine Institute. Chair, Department of Individualized Cancer Medicine. Senior Member, Division of Population Sciences. State of Florida Endowed Chair. ). Adapted from AHA Late Breaking . Trial Results Presented by. Arthur . J. Moss, . MD. Professor . of Medicine . University . of Rochester Medical . Center. November . 6, 2012. Los . Angeles. , . CA USA. Objectives of Treatment. GOLD 2018: Pharmacologic Treatment Recommendations. GOLD 2018: Pharmacologic Treatment Recommendations (. c. ont). GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D. ). Adapted from AHA Late Breaking . Trial Results Presented by. Arthur . J. Moss, . MD. Professor . of Medicine . University . of Rochester Medical . Center. November . 6, 2012. Los . Angeles. , . CA USA. ). Adapted from AHA Late Breaking . Trial Results Presented by. Arthur . J. Moss, . MD. Professor . of Medicine . University . of Rochester Medical . Center. November . 6, 2012. Los . Angeles. , . CA USA. Withdrawal of pharmacological therapy for heart failure in recovered dilated cardiomyopathy – a randomised trial TRED-HF Brian P Halliday MBChB PhD On behalf of Sanjay K Prasad (PI) , John GF Cleland (co-PI) Prof JG . Hakim, . Parirenyatwa. . CRS . Leader. Annual Research . Day; 8. th. . April 2016. TB- A Global Problem. TB Transformative Science Group (TB TSG). Agenda. Treatment & prevention of TB with or without HIV co-infection. Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts. By: Cole Smith PharmD Candidate 2021. University of Findlay. Preceptor: Katherine Crawford PharmD BCCP. POPular. TAVI Cohort B Trial Review. Background:. TAVI/TAVR- Transcatheter aortic valve implant/replacement. Utilized for patients who have aortic stenosis to help when their valve is not opening correctly. .